Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


LeadCare® II

Product Image
Product Description

LeadCare® II is the only CLIA-waived, point-of-care lead testing system that makes it possible to test, educate and intervene on-the-spot, in one visit. No need to send patients to an outside lab. No need to re-test due to sample problems at the lab. No risk of losing track of a child who needs treatment.

Who should be tested?

Federal law requires that all Medicaid eligible children be tested at 12 and 24 months and ages 36 to 72 months if they have not previously been tested.

Each state has guidelines for blood lead testing.  The American  Academy of Pediatrics (AAP) recommends that “children should be tested at least once when they are 2 years of age or, ideally, twice, at 1 and 2 years of age, unless lead exposure can be confidently excluded.”4

Contact us for information to help you determine your state’s specific testing requirements.

Who is at risk for lead exposure? Children are considered at risk if any of the following are true4:
•    Child lives in or frequently visits a home built before 1950, or a recently renovated home built before 1978
•    Child has a sibling or frequent playmate with elevated blood lead levels
•    Child's parent or primary caregiver works with lead. Examples include: battery recycling or manufacture, lead smelting, lead mining, auto repair, shipbuilding, construction, plumbing, and glass manufacture5
•    Child is a recent immigrant, refugee, or foreign adoptee.
•    Child has a household member who uses traditional, folk, or ethnic remedies or cosmetics or who routinely eats food imported informally (e.g., by a family member)

No safe levels. Evidence continues to grow that blood lead levels as low as 5 ug/dL may impair cognition3, with no minimum threshold yet identified.

Lifelong consequences of lead exposure include:
•    Six times higher likelihood of having a reading disability6
•    Being seven times more likely to drop out of high school6
•    Lower scores on neurobehavioral development7
•    Lower scores on tests for math, reading, nonverbal reasoning and short term memory7
•    Hypertension that contributes to adult cardiovascular disease8
•    Decline in IQ with every 1.0 μg/dL increase in blood lead9

Early diagnosis helps to quickly address the effects of lead exposure and provides impetus for lead abatement in homes.

LeadCare II is the only CLIA-waived point-of-care blood lead testing system. Employees of an office or lab operating under a CLIA Certificate of Waiver can administer the test.

Product LeadCare® II
Company Magellan Diagnostics
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Magellan Diagnostics
101 Billerica Ave, Building 4 North Billerica, MA 01862 USA

Tel: +1 800-959-5095
Fax: +1 800-755-5095
Email: orders@magellanbio.com



Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
72% Rise in Metastatic Prostate Cancer
Over the 2003-2013 period metastatic cancer has increased by an average of 72%, this could be caused by lax screening, more aggressive disease or both.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.

SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!